Latest news with #CNS
Herald Malaysia
a day ago
- Politics
- Herald Malaysia
Kyiv and allies welcome Pope Leo's Vatican peace talks offer
US President Donald Trump, Ukrainian President Volodymyr Zelenskyy, and several of Kyiv's European allies — including Paris and Berlin — gave a positive response May 19 to Pope Leo XIV's offer to host negotiations between Ukraine and Russia at the Vatican, according to Italy's prime minister. May 30, 2025 Pope Leo XIV receives a gift from Ukrainian President Volodymyr Zelenskyy during a meeting at the Vatican May 18, 2025. (CNS/Vatican Media) VATICAN: US President Donald Trump, Ukrainian President Volodymyr Zelenskyy, and several of Kyiv's European allies — including Paris and Berlin — gave a positive response May 19 to Pope Leo XIV's offer to host negotiations between Ukraine and Russia at the Vatican, according to Italy's prime minister. President Trump, President Zelenskyy, French President Emmanuel Macron, German Chancellor Friedrich Merz, Finnish President Alexander Stubb, Italian Prime Minister Giorgia Meloni, and European Commission President Ursula von der Leyen held a joint phone call following a separate conversation between Trump and Russian President Vladimir Putin. During the call, 'the Holy Father's willingness to host peace talks at the Vatican was viewed positively,' Meloni said in a statement. The call, she added, aimed 'to work toward the immediate opening of negotiations between the parties, in hopes of securing a cease-fire as soon as possible and laying the groundwork for a just and lasting peace in Ukraine.' In remarks to representatives of Eastern Christian churches recently, Pope Leo XIV offered to mediate global conflicts, including the war in Ukraine. 'The Holy See is available for enemies to meet and look each other in the eye, so that nations may regain hope and the dignity that belongs to them — the dignity of peace,' he said. Referencing the many ongoing conflicts around the world — 'from the Holy Land to Ukraine, from Lebanon to Syria, from the Middle East to Tigray,' in Ethiopia, 'and to the Caucasus' — Pope Leo lamented the violence and called for efforts toward peace. 'I will do everything I can to help peace take root,' he vowed. Over the weekend, he also received US Vice President JD Vance in a private audience. Cardinal Pietro Parolin, Vatican secretary of state, confirmed the pope's willingness to host a 'direct meeting' between Ukrainian and Russian leaders, according to media reports. --LCI (https://
Business Standard
a day ago
- Business
- Business Standard
Marksans Pharma gets regulatory nod for marketing type-2 diabetes medication in UK
Marksans Pharma said that its UK-based wholly owned subsidiary Relonchem has received marketing authorization for Metformin Hydrochloride oral solution product from UK Medicines & Healthcare Products Regulatory Agency. Metformin Hydrochloride is a widely prescribed medication used for the management of type-2 diabetes, particularly in patients who require oral liquid formulations due to difficulty in swallowing tablets. This regulatory approval would enable Marksans Pharma to market and distribute the said oral solution in the UK. Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally. The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24. The scrip rose 0.38% to currently trade at Rs 261.35 on the BSE.
Muscat Daily
3 days ago
- Business
- Muscat Daily
CNS Middle East and Fujifilm showcase advanced multifunction printers
Muscat – CNS Middle East, a leader in innovation and technology across the Middle East, in partnership with Fujifilm, a global leader in imaging and printing technologies, hosted an exclusive event on Monday, 26 May at the Intercontinental Hotel Muscat to unveil Fujifilm's latest Multifunction Printing (MFP) technology in the Omani market. The event brought together key decision-makers, IT leaders, and industry professionals from across Oman's enterprise, government, and SME sectors, who gathered to explore how Fujifilm's advanced MFPs are redefining the future of workplace printing. Attendees had the opportunity to witness live demonstrations of the state-of-the-art devices, followed by an interactive Q&A session with experts from CNS and Fujifilm. Fujifilm's MFPs, now available in Oman through CNS, are equipped with innovative LED print technology—delivering superior print quality, faster output, energy efficiency, and overall cost savings. The solutions also align with the region's growing sustainability priorities, making them ideal for organizations seeking to modernize their printing infrastructure without compromising on environmental responsibility. Cengiz Metin, General Manager, Device Technology Division at Fujifilm Middle East, added, 'We are proud to partner with CNS to bring our innovative technology to the Omani market. The engagement and feedback we received from local organizations during the event were truly encouraging. Together with CNS, we are empowering businesses with tools that enhance productivity. This is a clear display of our joint commitment to shaping the printing landscape in Oman.' Khodor Ezzeddine, Division Manager, Printing Solutions at CNS Middle East, commented, 'We were thrilled by the strong interest and positive response at the event. This turnout reaffirms the growing demand for next-generation printing solutions in Oman. Our collaboration with Fujifilm is centered on providing high-performance, sustainable technology that meets the evolving needs of Omani businesses and beyond.' The successful launch event marks a key milestone in the ongoing collaboration between CNS and Fujifilm, underscoring their shared commitment to delivering reliable, high-performance printing solutions that drive digital transformation across Oman – enabling organisations to streamline operations, enhance productivity, and achieve greater efficiency.
Zawya
3 days ago
- Business
- Zawya
CNS Middle East and Fujifilm showcase advanced multifunction printers at exclusive Muscat event
Muscat, Oman: CNS Middle East, a leader in innovation and technology across the Middle East, in partnership with Fujifilm, a global leader in imaging and printing technologies, hosted an exclusive event on Monday, 26 May at the Intercontinental Hotel Muscat to unveil Fujifilm's latest Multifunction Printing (MFP) technology in the Omani market. The event brought together key decision-makers, IT leaders, and industry professionals from across Oman's enterprise, government, and SME sectors, who gathered to explore how Fujifilm's advanced MFPs are redefining the future of workplace printing. Attendees had the opportunity to witness live demonstrations of the state-of-the-art devices, followed by an interactive Q&A session with experts from CNS and Fujifilm. Fujifilm's MFPs, now available in Oman through CNS, are equipped with innovative LED print technology—delivering superior print quality, faster output, energy efficiency, and overall cost savings. The solutions also align with the region's growing sustainability priorities, making them ideal for organizations seeking to modernize their printing infrastructure without compromising on environmental responsibility. Cengiz Metin, General Manager, Device Technology Division at Fujifilm Middle East, added, 'We are proud to partner with CNS to bring our innovative technology to the Omani market. The engagement and feedback we received from local organizations during the event were truly encouraging. Together with CNS, we are empowering businesses with tools that enhance productivity. This is a clear display of our joint commitment to shaping the printing landscape in Oman.' Khodor Ezzeddine, Division Manager, Printing Solutions at CNS Middle East, commented, 'We were thrilled by the strong interest and positive response at the event. This turnout reaffirms the growing demand for next-generation printing solutions in Oman. Our collaboration with Fujifilm is centered on providing high-performance, sustainable technology that meets the evolving needs of Omani businesses and beyond.' The successful launch event marks a key milestone in the ongoing collaboration between CNS and Fujifilm, underscoring their shared commitment to delivering reliable, high-performance printing solutions that drive digital transformation across Oman - enabling organizations to streamline operations, enhance productivity, and achieve greater efficiency. About CNS Middle East Established in 1987, CNS Middle East, a Ghobash Group Enterprise, is a premier technology solutions provider dedicated to driving future advancements across the region. With a robust team of over 800 technology specialists, CNS excels in cloud, cybersecurity, digital infrastructure, fintech and business application solutions, along with emerging technologies, plus managed and engineering services. CNS serves as a trusted partner for businesses seeking transformative technology solutions and is committed to helping clients achieve mission-critical objectives through innovation and best-in-class services. For more information, visit or write to info@ You can also follow CNS Middle East on LinkedIn. Source: AETOSWire Contacts: Tony Hamad Group Marketing Director
Yahoo
23-05-2025
- Business
- Yahoo
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
Poster presentation to highlight Phase 1 results that support ABX-002 Phase 2 development as an adjunctive treatment for major depressive disorder and bipolar disorder depression SAN DIEGO, May 23, 2025--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist designed to enhance the CNS benefits of thyroid hormone biology for patients suffering from major depressive disorder (MDD), bipolar disorder depression, and other affective illnesses. "We are excited to share the Phase 1 findings at ASCP, which demonstrated a favorable safety and tolerability profile and enhanced CNS target engagement with ABX-002, and support its evaluation in the ongoing Phase 2 trials in major depressive disorder and bipolar depression," said Gudarz Davar, M.D., Executive Vice President, Head of Research and Development for Autobahn. "Despite availability of existing therapies, many individuals with MDD and bipolar depression struggle to achieve adequate relief. Our team remains deeply committed to developing novel, CNS-targeted treatments that we believe have the potential to meaningfully improve the lives of those affected by these debilitating conditions." Results from the completed Phase 1 trial of ABX-002 in healthy volunteers demonstrated ABX-002 was safe and well tolerated, with no serious adverse events observed. Additionally, ABX-002 demonstrated dose proportional PK and clinical evidence of CNS target engagement consistent with brain-activating thyroid effects, helping inform Phase 2 dose selection. The company is currently evaluating ABX-002 as a potential adjunctive treatment for people with major depressive disorder in the ongoing AMPLIFY Phase 2 trial and as a potential adjunctive treatment for bipolar depression in a separate ongoing Phase 2 trial. Details for the poster presentation can be found below: Title: A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Thyromimetic ABX-002 in Healthy Adult ParticipantsDate: Thursday, May 29, 2025Time: 11:30 a.m. – 1:15 p.m. MTPresenter: Bridgette Franey, M.D., Senior Medical Director, Global Medical Lead - Clinical Development, Autobahn TherapeuticsLocation: Fairmont Scottsdale Princess, Scottsdale, AZ The abstract and additional details can be found on the 2025 ASCP annual meeting website. About Autobahn TherapeuticsAutobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company's pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit About ABX-002ABX-002 is an orally administered, potent and selective thyroid hormone beta receptor (TRβ) agonist designed to enhance the CNS benefits of thyroid hormone biology while also reducing the peripheral liabilities of synthetic thyroid hormone (e.g., triiodothyronine, T3), a treatment which has shown efficacy in numerous placebo-controlled human studies across MDD and bipolar disorder depression. Thyroid hormone agonism has demonstrated activity on cellular energy metabolism pathways, which play an important role on the regulation of brain bioenergetics and may be uniquely suited to address symptoms of atypical depression, a highly prevalent and underserved sub-population of MDD. In nonclinical and clinical studies, ABX-002 has demonstrated optimized PK properties, target engagement in brain regions associated with depression, and an attractive safety and tolerability profile. View source version on Contacts Investors: Alex StrausTHRUST Strategic Communicationsalex@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
